Pharmacokinetics of cefuroxime in bone and cartilage

Recruiting

Conditions: The pharmacokinetics of cefuroxime in the human body will be investigated

Registration Number: DRKS00012880

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 80

Inclusion Criteria

Adult Patients

women and men

from 20 to 85 years

undergoing an elective hip replacement therapy

or spine surgery

Signed informed study consent form

Legally competent patient

Exclusion Criteria

Subject exclusion criteria:

Patients who are unable to consent

Patients unwilling to consent

Patients who retracted their consent

Pregnant women,

Patients with impaired renal or liver function,

Patients with anemia,

Children

Young adults that are still growing

Breast-feeding women,

Patients with leucocytopenia,

Patients with thrombocytopenia

Patients hypersensitive or allergic to cefuroxime, cephalosporines or beta-lactame antibiotics

Patients with prior traumatic surgery within six month

Patients with past or present osteomyelitis

Patients with impaired cardiac function

Patients with high body mass index

Patients taking diuretics or aminoglycoside antibiotics

Patients with candida infections

Patients with colitis

Patients with other abdominal infections

Patients with abdominal infection

Patients receiving an additional administration of cefuroxime due to longer duration of surgery or other clinical reasons within the sample collecting period

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The endpoint of the study is the calculated concentrations of cefuroxime in the different tissues taken at different times. The concentration is determined by high performance liquid chromatography (HPLC). This analysis is started when all 80 patients have been discharged from the hospital.

Secondary Outcome Measures